TW200304828A - Extract of processed panax genus plant, the preparation method thereof, and compositions containing the same - Google Patents

Abstract

The present invention relates to processed extract of Panax genus plant, the preparation thereof and compositions containing the same having anticancer or anti-allergic activity. More particularly, the present invention relates to a processed ginseng product with enhanced pharmacological effects due to serial treatment i.e., acid-treatment or heat-treatment of a Panax genus plants and subsequent bio-converting treatment such as lactic fermenting and intestinal-bacterial fermenting process so as to make a ratio of ginsenoside (Rk2 + Rh3 + protopanaxadiol + 20- dehydroprotopanaxadiol) to (Rg3 + Rg5 + Rk1) of above 0.1. The extract of processed Panax genus plant in the present invention has inhibitory effect for cancer or allergic diseases and it is useful in the prevention or treatment of cancer or allergic diseases.

Description

200304828 (ii) Description of the invention t Technical field 3 to which the invention belongs 3 Technical field The present invention relates to processed extracts of the genus Polygonum, its manufacturing method, and compositions containing anti-cancer and anti-allergic activities. More specifically, the present invention relates to a processed human salamander product and an extract thereof. The extract has a strengthened pharmacological effect through a series of treatments, that is, an acid treatment or heat treatment of a plant of the genus Salamander and a subsequent biotransformation treatment. , Such as: lactic acid fermentation and enteric bacteria fermentation processing so that the ratio of human soap (Rh + Rhs + protozoan + 20-dehydroprotoco human glycol) to (Rg3 + Rg5 + Rkl) exceeds 〇1 10 〇L · Jt has many genus known to belong to the genus Polygonaceae, such as the human being distributed or planted in the Far East Asia, the Western Village in the United States or Canada, the Panax notoginseng in China, and the eastern region of North America Trefoil 曰, Japanese, Chinese and Neptune Japan 蔘, Himalayan fake pheasant in Nepal, Vietnam 蔘, Vietnam, Ai 蔘 (P⑽ax e / eg 仙 · 〇Γ), Wang 蔘 (ρα like JC㈣) Sigh / sorry) and Panax bipinratifidus. So far, human salamander has been widely recognized as a representative nutritional tonic. Recently, many scientific studies on the chemical constituents and pharmacological effects of human puppets have been reported. 20 The mysterious pharmacological effects have attracted the attention of modern scientific methods. So far, it is known that human pupae have various pharmacological effects such as: prevention of aging, anti-arteriosclerosis, treatment of hyperlipidemia, treatment of liver dysfunction, improvement of liver function, protection from radiation damage, immune enhancement, enhancement of brain function, antithrombotic, Anti-stress, anti-diabetes, anti-hypertensive, anti-cancer effects, etc. 200304828 发明 Description of the invention It is known that the main component of the plant of the genus Zizania is the Malaysian tree-like name. The main saponins in humans are human lepto, Rb2, Rc, Rd, and RgdRe. The activities of ^ are different depending on their chemical structure. 5 10 There have been many attempts to process or modify human dad plants to increase their pharmacological potency, in particular, to modify the human saponins. Korean Patent Publication No. 1 (M99, ㈣1), which was proposed on May 23, 1996 (a method for preparing a processed human puppet containing a high content of bismuth and osmium in humans', by subjecting the human puppet to high temperature treatment to Obtaining processed humans with an enhanced potency that is different from the original form. Korean Patent Publication No. 101996_004217, filed on February 22, 1996-Method for large-scale production of 4-metabolites such as use Enterobacteria are known as compound b. However, it is related to chemically changing the saponin component by a series of treatments including acid or heat treatment or 15 combinations thereof and subsequent fermentation by lactic acid bacteria or enteric bacteria. The method for the preparation of processed human anthracis has not been disclosed or suggested. This method makes the human anthracite soap (Rk2 + Rh3 + protohuman diol + 20 dehydroprotohuman diol) to (Rgs + Rg5 + The ratio of Rki) exceeds 0 ". However, recently, the method of heat-treating human beings at high temperature has been partially 20f inclusive, j». For example, Japanese Patent Application Publication No. (Sh〇) 62-15849 〇Reveal a high human soap content used to prepare a tissue culture The method of human beings' This method involves heat treating the tissue cultured human beings at a temperature of 110 to 160 ° C. However, it has disadvantages because it uses tissue cultured humans instead of ordinary humans, which are processed The product of human beings does not have the original form of human beings. 200304828, description of invention, and about the various components and pharmacological effects. The tissue cultured human is different from the naturally cultivated original humans. (Korea Biomedical Journal 16, p. 171) (1985)) and the method is complicated and uneconomical due to the tissue culture procedure. In addition, although the method of heat-treating humans at high temperature has been partially tried, the method is only used in the manufacture of cosmetics The method of tea or tea has not been performed on the pharmacological effects of heat-treated human tincture. The inventors of the present invention have conducted in-depth scientific research on the components and pharmacological effects of human tincture, especially the processing method of human tincture and the classics. Pharmacological activity of processed human pupae. As the result of this study, the inventors have found that because of the rare components that are present in the plants of the genus Pupae, the number of new components is also greatly increased. It is produced after a series of treatments that include acid or heat treatment or a combination thereof, followed by fermentation with lactic acid bacteria or enteric bacteria. The plant extract has new components that have not been discovered so far and exhibits substantially enhanced pharmacology Function, and the inventors have completed the present invention. 15 [Explanation] Summary of the Invention Therefore, an object of the present invention is to provide a solution containing human soap (Rk2 + Rh3 + proto-human diols + 20-dehydropro- human diols) ) To humans or their extracts with a ratio of (Rg3 + Rg5 + Rk〇) exceeding 0 · ι. 20 And, another object of the present invention is to provide by substantially containing ... acid or heat or a nettle combination thereof The step of processing the plant material belonging to the genus Hovenia, and the plant of Hovenia or its extract obtained by subsequent fermentation by lactic acid bacteria or enteric bacteria. Another object of the present invention is to provide a method for preparing the above-mentioned plants and extracts thereof. Another object of the present invention is to provide a pharmaceutical composition comprising the above-mentioned extract as an active ingredient or the saponin compounds isolated therefrom, and a pharmaceutically acceptable carrier, the active ingredient is an effective In an amount of 5 to treat or prevent human or mammalian cancer or allergic diseases. Another object of the present invention is to provide a method for treating or preventing mammalian cancer or allergic diseases, which comprises administering to the mammal an effective amount of the above-mentioned extract or the saponin compounds isolated therefrom, and Pharmaceutically acceptable carrier. 10 Another object of the present invention is to provide the above-mentioned extract or the saponin compounds isolated therefrom for use in the manufacture of a medicine for treating cancer or allergic diseases. DISCLOSURE OF THE INVENTION According to the present invention, the present invention provides a plant of the genus Polygonum or its extract, 15 which includes (Rk2 + Rh3 + proto-human diols + 20-dehydroproto-human diols) to (Rg3 + Rg5 + The ratio of Rk!) Exceeds 0.1, preferably exceeds 0.2, and more preferably exceeds 0.5.

The aforementioned pro-human fluorene glycol (PPD) and dehydropro-human fluorene glycol (DHPPD) include their isomers, mirror isomers, and non-image isomers, that is, 20 (20S) PPD, (20R ) PPD and 20 (21) -DHPPD, 20 (22) -DHPPD The present invention also provides the treatment of the plant material belonging to the genus Polygonum by essentially including: acid or heat or a combination thereof, and subsequent treatment with lactic acid bacteria or intestines The fungus fermentation step processes the obtained human sedge plant or its extract. 200304828 发明, description of the invention The above plants or extracts can be prepared by the following steps: 1. Ist step:

The Ist step is to subject the plant material to an acid or heat treatment step or a combination thereof as follows: 5 (1) Acid treatment step

Specifically, in the Ist step, the dried plant material belonging to the genus Hovenia, such as the root of Hovenia, is subjected to subsequent acid treatment; for example, about 1 to 50 times, preferably 20 to 50 times 0.01 to 50% (v / v%), preferably, 0.1 to 10% of an acidic component, preferably, acetic acid, citric acid, lactic acid, or 10 acidic flavored foods such as Schisandra, are added to the plant material; and subsequently Place in an incubator at a temperature range of 20 to 80 ° C, preferably at 40 to 70 ° C for a period of 1 to 48 hours, preferably 3 to 12 hours; organic solvents such as: butanol, methanol, ether, acetic acid Ethyl esters are added here and then extracted to obtain an extract soluble in organic solvents; finally, the extract 15 is neutralized with a base to obtain a chemically acidic Sagitta extract.

(2) Heat treatment step The heat treatment process can be used as another initial step for obtaining the present invention, that is, subjecting the dried plant material belonging to the genus Anthracis to a subsequent heat treatment; for example, the plant material is at 110 to 180 ° C temperature range, 20, preferably 120 to 140 ° C is treated for 0.5 to 20 hours, preferably 2 to 5 hours. The heating time varies with the heating temperature. Lower heating temperatures require longer heating times. The heating process can be performed by using hot air, water vapor, nitrogen, helium, carbon dioxide, or a mixed gas thereof. In order to increase the efficiency, the heating process can preferably be performed in an air-tight container such as high temperature and high pressure 10 200304828. The invention description is optional. Optionally, a small amount of water can be added to the container; in addition, preferably people蔘 can be immersed in water purely in a sealed container towel to be heated. A dry processed person laughs The processed person can be dried at a temperature lower than the heating temperature of the process, that is, to a temperature of 8G. (3) Obtained through a known method. Or if needed it can be further processed to optionally, the processed person can be extracted in a known way

Take to obtain-Processed human stock extract. Specifically, the processed human extract is extracted by using a solvent, and then the solvent is subjected to a concentration of 10 or freeze-dried to obtain a processed human extract which is a dry powder. Solvents which can be used here include water, lower alcohols such as methanol, ethanol, etc., lower ketones such as acetone, methyl ethyl ketone, etc., supercritical fluids, or mixed solvents thereof. 15 Plant materials that can be used include, but are not limited to, humans

The plant itself, such as fresh human salamander, white salamander, red salamander, human salamander's fine roots or human salamander leaves or their extracts, can be classified by users as finely cut or crushed, processed salamander products, Other by-products of horsesane saponins, preferably, mandarin duck, western mandarin duck, panax notoginseng, trefoil mandarin duck, Yueben mandarin duck, Himalayan fake rattle, Vietnamese mandarin duck, Ayer mandarin duck, Wang mandarin duck , Byping 蔘 and An ge 、 (P 果实 π roots, stems, petals, leaves, fruits and their tissue cultures and extracts. Before the next 2nd step, the above (1) and (2) processes can be individually Applied to plant materials in situ or in combination. 11 200304828 发明, Description of the invention 2. 2nd step: Fermentation step The extract obtained from the Ist step is then subjected to a subsequent biotransformation treatment such as fermentation treatment with lactic acid bacteria or enteric bacteria as follows: For example Lactic acid bacteria or enteric bacteria are added to the 5 extract obtained from the Ist step and are cultured for 8 hours to 8 days at a temperature range of 20 to 50 ° C, preferably 25 to 40 ° C, preferably 24 hours to 3 days to obtain a bacterially treated extract

The culture time varies depending on the bacterial genus to be used.

The lactic acid bacteria that can be used include any lactic acid bacteria that can transform human soaps Rg3, Rg5 and 10 Rk! To metabolize adult soaps Rh2, Rh3, Rk2, proto-human diol (PPD) and dehydropro-human diol (DHPPD) Preferably, the lactic acid bacteria belonging to the genus Bifidobacterium are more preferably selected from the group consisting of: Bifidobacterium infantis, Bifidobacterium bifidus, Lactobacillus stagnation, Clostridium butyricum, K-103 Bifidobacterium, K-506 Bifidobacterium, K-513 Bifidobacterium, K-525 Bifidobacterium 15, KK-1 Bifidobacterium, and KK-2 Bifidobacterium (disclosed at drd P / zarm. And later ·, 21, p54-61, 1988) at least one of the groups formed by households or a mixture thereof. Intestinal bacteria that can be used include any human soap Rg3, Rg5 and

Rk! Enterobacteria that metabolize adult 蔘 soap Rh2, Rh3, Rk2, proto-human diol (PPD), 20 and dehydroproto- human diol (DHPPD), preferably belonging to the genus Bacillus and Clostridium Genus and Eubacteria, more preferably, selected from the group consisting of: JY-6 bacilli (disclosed at 5ζ · (9 / · corpse / mrm. 5w // ·, 23, ppl481-1485, 2000), dung Wercor / s), Clostridium K-60 (disclosed in Biol · Parm. Bull ·, to be published), L-8 true bacteria (disclosed in 12 200304828), invention description

Biol, Pharm, Bull, to be published). In addition to the above steps, the saponin fraction or saponin compounds are further separated from the extract obtained from the above 2nd step, and subsequent processes can be used. 5 3. 31 ^ step: separation process

A pharmacologically active fraction or a saponin compound is separated from the extract obtained from the 2nd step. Lower alcohols such as alcoholic water, methanol, and ethanol can be used as the extract or separated from the extract obtained from the 2nd step. Suitable solvents for parts or compounds. 10 In addition, the active ingredient can be extracted or separated by using special extraction methods such as supercritical fluid extraction (SFE) to obtain a partially purified saponin fraction and further, by means of a silica gel column chromatography method. To separate a variety of saponins.

After the above steps, in addition to the above steps, if necessary, subsequent 15 processes such as freeze-drying drying processes for beverages or food, stirring or dilution processes may be used. The subsequent steps may select either or both depending on the final product form of the present invention. 4. 4th step: Drying process 20 (1) The extract of Amaranthus plant obtained from step 2 or 3 above is concentrated under reduced pressure and then dried, such as freeze drying or spray drying (2) From step 2 above Or 3 The extract of the genus Polygonum is centrifuged to remove impurities and precipitates and the supernatant is depressurized 13 200304828 玖, description of the invention is concentrated and then dried, such as freeze-drying or spraying dry. After the Ist step to the 2nd step process, after the acid treatment or heat treatment of the Ist step, saponins contained in plant materials such as: human soap Rb !, Rb2, Rc, Rd, etc., are transformed into chemically modified Human soaps such as 5: Rg3, Rg5, Rk !, etc., and then the carbohydrate auxiliary group at position 3 of the modified saponin are further degraded to form a further modified saponin comprising: Human soap soap Rk2, Rh2, Rh3, PPD, DHPPD.

In particular, the processed human erbium product according to the present invention has a ratio of human erbium soap (Rk2 + Rh3 + proto- human diol + 20-dehydroproto-man diol) to (Rg3 + 10 Rg5 + Rk!) Above 0.1, the physiological activity exhibited is superior to that of the previously processed human puppet products. The content of human processed soap Rk2, Rh2, Rh3, PPD and DHPPD of the previously processed human puppet products is almost zero.

Therefore, the present invention also provides a method for preparing the above-mentioned plant or its extract, which method basically comprises: a step of treating the plant material belonging to the genus 15 genus by acid or heat or a combination thereof, and then using lactic acid bacteria or intestines The process of bacteria fermentation. In addition, the present invention provides a method for preparing a pharmacologically active separation moiety or a saponin compound, comprising the steps of subjecting the extract prepared by the above step 2 to extraction or separation with a lower alcohol to obtain a purified separation 20 fractions; and additionally, the fractions were subjected to silica gel column chromatography to separate the saponin compounds. The lower solvents include methanol, ethanol and butanol. The present invention also provides a pharmaceutical composition comprising the above-mentioned extract or saponin compound prepared by the above process as an active ingredient, and a pharmaceutical 14 200304828 玖 'invention description. ::: ....' Λ: ... V: :: .. 二 :: Ό:. ^ '' ';;:' .L " acceptable carrier on 'L' This active ingredient is an effective amount to treat or prevent human or mammalian diseases, in particular, cancer Or allergic diseases. In particular, the present invention provides a pharmaceutical composition comprising the above-mentioned extract or saponin compound with an activity of 5 10 15 20 parts, selected from the group consisting of: human beings

, 2〇 (r) -human red, 20⑻ · human 蔘% 3, 20⑻renzhai soap, 2__renqin factory original human diols and their combination and __ pharmacologically acceptable Next, the active ingredient is an effective amount to treat or prevent human or mammalian cancer or allergic diseases. The above cancers include liver cancer, lung cancer, skin cancer, ovarian cancer, blood cancer, uterine cancer, and the like, and the allergic diseases include rhinitis, dermatitis, asthma, autoimmune disease, and the like. The present invention also provides a method for treating or preventing mammalian cancer or allergic diseases, comprising: administering to the mammal an effective amount of the above-mentioned extract and a saponin compound isolated therefrom, and a pharmaceutically acceptable carrier .

The present invention also provides the use of the above-mentioned extract or the saponin compounds isolated therefrom for the manufacture of a medicine for treating cancer or allergic diseases. In particular, the above-mentioned saponin compounds include Re, Rg !, Rf, F1, F4, Rhi, Rg5, 20% Saisai 3, 20%-Human% 3, 20 (S)-Human Size 2, 20 (R) -Human Soap Rh and Protohuman Sodium Glycol. According to a method of use, the composition of the present invention may additionally include a conventional carrier, an adjuvant or a diluent. Preferably, the carrier is used as a suitable substrate according to the use and application method, but is not limited thereto. A suitable diluent system 15 200304828 玖, description of the invention is displayed in Remington, s pharmaceutical Λ

Science, Mack Publishing co, Easton PA). In the following, the subsequent formulation methods and excipients are merely examples and do not limit the invention. · 5 The composition according to the present invention can be provided as a pharmaceutical composition, which can be provided with a pharmaceutically acceptable carrier, adjuvant or diluent, such as: lactose, glucose, sucrose, sorbitol, mannitol, wood Sugar alcohol, erythritol, maltitol, starch, acacia, alginate, gelatin, calcium phosphate, lithostamate # 5, cellulose, fluorenyl cellulose, polyethylenetetrahydro-sigma-pylonone, Water, hydroxymethyl benzoate, hydroxypropyl benzoate, talc, magnesium stearate, and minerals. The formulation may additionally include fillers, anticoagulants, lubricants, humectants, flavoring agents, emulsifiers, preservatives and the like. The composition of the present invention may be formulated to provide a rapid, sustained or delayed release of the active ingredient after they are administered to a patient by using any conventional method. 15 For example, the composition of the present invention can be dissolved in oil, propylene glycol, or other solvents commonly used to produce an injection. Examples of suitable carriers include, but are not limited to, physiological saline, polyethylene glycol, ethanol, vegetable oil, isopropyl myristate 4 '. For topical administration, the compounds of the invention can be formulated in ointment and cream forms. 〇The pharmaceutical formulation containing the composition of the present invention can be prepared into any type, such as an oral dosage form (powder, tablet, capsule, soft capsule, liquid medicine, syrup, gel pill, powder, sachet, granule), Or topical preparations (creams, ointments, emulsions, colloids, sesame oils, patches, spray solutions, aerosols, and phase A), or injectable preparations (solutions, suspensions, emulsions). 16 200304828 发明, description of the invention. In the pharmaceutical dosage form, the composition of the present invention can be used in the form of a pharmaceutically acceptable salt thereof, and can also be used alone or suitable related persons or mixed with other pharmaceutically active compounds used. The desired dosage of the extract or composition of the present invention varies depending on the individual's situation 5 and weight, severity, dosage form, administration route and period, and can be selected by those skilled in the art. However, in order to obtain the desired effect, it is generally recommended to administer the extract or composition of the present invention in an amount ranging from 0.01 to 10 g / kg, preferably, 1 to 5 g / kg body weight / day. This dose can be administered in single or divided doses. From the point of view of the composition, the composite herbal composition may exist between 10 and 80% by weight, preferably 0.5 to 50% by weight, based on the total weight of the composition. The pharmaceutical composition of the present invention can be administered to a recipient animal such as a mammal (rat, mouse, domestic animal, or human) through various routes. All modes of administration are contemplated, for example, administration by oral, rectal or intravenous, 15 muscle, subcutaneous, intradermal, intraspinal, epidural or intraventricular injections. The inventors have performed in vitro and in vivo experiments to exemplify that the anticancer and antiallergic effects of this composition are equal to or have potential for traditional antiallergic drugs. These experiments include cancer cell lines and the use of rBL_2H3 Cell obesity cell analysis test in rats, mouse model test passive skin immediate 20 allergic reaction, inhibition test of allergic reaction on the back of mice after administration of dinitro-bovine serum albumin (DNP-BSA) The protective effect against the allergic and inflammatory response of IgE serum in mice. Therefore, the above composition has been proven to be very useful in preventing or treating cancer and allergic diseases. The composition of the present invention provides prevention of cancer and allergic diseases. Therefore, the composition of the present invention is very useful for patients with various cancers and allergic diseases. According to another aspect, another object of the present invention is to provide a health food for preventing cancer or allergic diseases, which comprises the above-mentioned extract 5 prepared by the above-mentioned method and a nutritionally acceptable additive.

The above composition can be added to food, additives or beverages to prevent cancer or allergic diseases. For the purpose of preventing cancer or allergic diseases, wherein the amount of the above-mentioned extract or compound in food or beverage may generally be from about 0.1 to 0.15 w / w%, preferably, 1 to 10 w / w% of healthy food The total food weight of the group of 10 ingredients, and the ratio of 1 to 30 g, preferably 3 to 10 g, to 100 mL of the healthy beverage composition.

The composition of the present invention provided in the health drink contains the above-mentioned extract or compound in the indicated proportion as a basic component, and the other liquid components are not particularly limited, just like other components in a traditional beverage may be Various 15 deodorants or natural carbohydrates. The aforementioned natural carbohydrates are: monosaccharides such as glucose and fructose; disaccharides such as maltose and sucrose; traditional sugars such as dextrin and cyclodextrin; and sugar alcohols such as xylitol, And erythritol. Other deodorants other than the foregoing, natural deodorants such as Somatian, stevia extracts such as: leaudioside A, glycyrrhizin, etc., and synthetic deodorants such as saccharin, Aspartame and the like can be advantageously used. The amount of the above-mentioned natural carbohydrates generally ranges from about 1 to 20 g, preferably 5 to 12 g to 100 mL of the beverage composition. Ingredients other than the aforementioned composition are various nutrients, vitamins, 18 200304828 玖)-clearly stated · Minerals or electrolytes, synthetic flavoring agents, colorants, and modifiers such as cheese and chocolate pectin, pectin Acids and their salts, alginic acid and its salts, organic acids, protected colloidal adhesives, pH control agents, stabilizers, preservatives, glycerol, alcohols, carbonizing agents used in carbonated beverages. The other components other than the foregoing 5 may be fruit juices for the preparation of natural fruit juices, fruit juice drinks and fruit and vegetable beverages, wherein these components may be used independently or in combination. The proportion of these components is less important but is generally from 0 to 20 w / w% per 100 w / w% of the present composition. 0 Examples of foods that can be added containing the aforementioned extracts are various foods, 10 drinks, gums, vitamin complexes, health-enhancing foods, and the like. It will be apparent to those skilled in the art that various changes and modifications can be made in the composition and the use and preparation of the present invention without departing from the spirit or scope of the invention. 15 [Embodiment]

BEST MODE FOR CARRYING OUT THE INVENTION The present invention is explained more specifically by the following examples. However, it should be understood that the present invention is not limited by these examples in any way. 20 Comparative Example 1 Preparation of the Extract of the Unprocessed Hovenia Plant 60% ethanol was added to 20 g of each of the air-dried and sliced Root of Mangosteen, Saigo ’s Root and Panax notoginseng roots and was refluxed For a total of three hours, and concentrated in a vacuum to obtain 4.5, 4.0, and 3.7 g of extracts of human radish root, syringa radiata, and notoginseng root respectively. 19 200304828 发明, Description of the invention Comparative Example 2 Preparation of an extract of an acid-treated human Polygonum plant 1000 ml of a water system containing 0.1% lactic acid (v / v%) was added to 20 g of each air-dried and sliced The mandarin duck root, the mandarin duck root, and the panax notoginseng root were cultivated at 60 ° C for 5 hours, and the cultured system was extracted with a butanol solvent to obtain 2.5, 2.8, and 3.2 g of acid treated respectively. Extracts from the roots of the mandarin duck root, yarrow root, and notoginseng root.

Comparative Example 3. Preparation of heat-treated extracts of human sedges 10 Air-dried and sliced human sedge roots, sassafras roots, and notoginseng roots were placed in a high-temperature autoclave and then borrowed 130 ° C The steam was heated for 3 hours. 60% ethanol (v / v%) was added thereto and then refluxed for a total of three hours to obtain 42, 35, and 37 g of extracts of mandrill root, prickly pear root, and notoginseng root respectively. 15

Example 1 Preparation of Extracts of Processed Anemone Plants Each heat-treated extract prepared by Comparative Example 3 was an extract equivalent to the amount of lg plant material and was dissolved in 20 mL of distilled water These plant materials are human coriander root, western coriander root, and notoginseng root. 20 lOOmg of Clostridium K-60 (wet weight) was added thereto and then cultured at 37 ° C for 72 hours. The culture was centrifuged and the supernatant was concentrated and dried to obtain 550, 530, and 430 mg of processed human yam root, yarrow root, and notoginseng root extracts, respectively. 20 200304828 发明 、 Explanation Example 2 · Preparation of processed extracts of human genus Polygonum, each heat-treated extract prepared by Comparative Example 3, which is an extract equivalent to the amount of lg plant material, is Dissolved in 20mL of distilled water, these plant materials are human coriander root, yarrow root, and notoginseng root5. 50 mg of K-506 Bifidobacterium (disclosed at "rc / z. Corpse / ζαπ 21, ρ54-61, 1988), 50 mg of K-103 Bifidobacterium (disclosed at drcA. PAarm. 21, ρ54-61 , 1988) and 50 mg of KK-1

The fork strain was added here and was then cultured at 37 ° C for 72 hours. The culture system was centrifuged and the supernatant was concentrated and dried to obtain 10 580, 450, and 41 Omg of processed extracts of mandarin duck root, yarrow root, and notoginseng root respectively. Example 3 Preparation of Extracts of Processed Hovenia

Each of the acid-treated extracts prepared by Comparative Example 2 was an extract having a phase 15 equal to the amount of 1 g of plant material, and was dissolved in 20 mL of distilled water. As well as the panax notoginseng root. 50 mg of JY-6 anaerobic bacteria, 50 mg of L-8 true bacteria, and 50 mg of the faecal anaerobic strain were added thereto and then cultured at 37 ° C for 48 hours. The culture system was centrifuged and the supernatant was concentrated and dried to obtain 580, 630, and 450 mg of processed human yam root, yarrow root, and notoginseng root extract respectively. Example 4 Preparation of Extracts of Processed Human Polygonum 21 200304828 玖, Description of the Invention The acid-treated extract prepared by Comparative Example 2 is an extract equivalent to the amount of lg human root It was dissolved in 20 mL of distilled water. 50 mg of K-506 Bifidobacterium (disclosed at drcA · PAarm. 21, ρ54-61, 1988) and 50 mg of K-103 Bifidobacterium (disclosed at 5 Jrd corpse / mrm · 7? Α ·, 21, ρ54-61, 1988) line was added here and then cultured at 37 ° C for 72 hours. The culture system was centrifuged and the supernatant was concentrated and dried to obtain 430 mg of an extract of processed human roots.

Example 5 Preparation of Extracts of Processed Anemone Plants 10 The acid-treated extract prepared by Comparative Example 2 was an extract equivalent to the amount of 1g of mandarin root, which was dissolved in 20mL containing 1% citric acid in distilled water and cultured at 60 ° C for 5 hours. The pH of the culture was adjusted to 6.8-7.0 with NaOH or glucuronic acid and centrifuged to obtain the supernatant. 50mg of K-506 Bifidobacterium and 50mg of

15 KK-2 Bifidobacterium (wet weight) was added here and then cultured at 37 ° C for 48 hours. The culture was centrifuged and the supernatant was concentrated and dried to obtain 350 mg of an extract of processed human scallion root. Example 6 Preparation of Extract of Processed Anemone Plants 20 lg of sliced anemone leaves were dissolved in 200 mL of MeOH, refluxed for 3 hours and then the solvent was removed under reduced pressure. The remaining residue was suspended in distilled water and extracted with ether to remove ether-soluble compounds. The remaining aqueous layer was extracted with butanol and concentrated to obtain a fraction that can be dissolved in butanol. The butanol-soluble separation part was heated at 130 ° C for 3 hours and then 20 mL of distilled water was added to dissolve the solution. 100 mg of a fresh human intestinal bacterial community was added here, and then cultured at 37 ° C for 48 hours. The culture was centrifuged and the 5 supernatant was extracted with 50 mL of butanol, concentrated in a vacuum and dried to obtain 100 mg of an extract of processed mandarin duck leaf.

Example 7. Preparation of Extracts of Processed Anemone Plants 10 L of MeOH was added to 1 kg of dried 6-year-old Amaranth, 10 and extracted five times at room temperature for a total of 48 hours. Concentrated to obtain 50 g of methanol-soluble extract (yield: 5%). 300 mL of distilled water was added thereto and thereafter suspended to prepare a suspension solution thereof. 500 mL of butanol was added thereto and then fractionated three times to obtain 15 g of a saponin fraction.

15 1000 mL of distilled water containing 0.1% lactic acid was added to 15 g of the above-mentioned saponin separation portion and cultured at 60 ° C for 5 hours to obtain acid-treated human salamander. The culture line was neutralized with NaOH and diluted with an optimal amount of water. 15 g of the KK-1 bifidobacterium (order number: KCCM 10364) and 15 g of the KK-2 bifidobacterium (order number: KCCM 10365) line 20 were added thereto and then cultured at 37 ° C for 72 hours. The culture was extracted twice with 1000 ml of butanol, concentrated in a vacuum and dried to obtain a processed saponin fraction of 8.5 g, which was thawed in distilled water and fresh human intestines. Bacterial community lines were added here, and the lines were cultivated at 37 ° C for 48 hours. The culture system was centrifuged and the supernatant was extracted with 50 mL of saturated butanol, concentrated in a vacuum and dried to obtain 100 mg of a processed saponin fraction. 8.5g of the saponin separation fraction was subjected to silica gel column chromatography (3.5x60cm, developing solution: CHC13-5 MeOH = 10: l) to obtain 20 (S) of 100mg-human g3 and 20 (R of 50mg) ) -Humans, 10mg of humans, 10mg of

Humans offer 1, 70mg of 20 (S) -Human i | h2, 8mg of 20 (R) -Humans 2, 15mg of people advise 3, 10mg of people, soap Rk2, 10mg of 20 (S) -Proto human diol, 2 mg of 20 (R) -proto human 10 diol, 5 mg of 20-dehydroproto human diol, 15 mg of human germ soap Rh !, and 12 mg of human gerantriol. Experimental Example 1: Content Analysis Experiment

Each of the 15 extracts obtained by Comparative Examples 1, 2, 3 and Examples 1, 2, 3 was an extract equivalent to 500 mg of plant material, which was suspended in distilled water and extracted with n-BuOH . The butanol-soluble layer was concentrated in vacuo and the remaining residue was dissolved in 5 mL of MeOH. The solution was filtered through a membrane and injected into HPLC to measure the amount of the saponin component therein. 20 The analysis method is based on the literature (Kwon W a / ·, J.

Chromatography, A 921, pp335-339, 2001) The method disclosed is slightly changed as follows: Column: LiChrosorb RP-18 24 200304828 玖, Description of the invention Elution solvents: A = H20, B = CH3CN, gradient washing 0 min (B 15%); 10 min (B 34.5%); 5 min (B 47.5%); 40 min (B 80%); 50 min (B 100%) Flow rate: lmL / min o 5 Detector: The volatile light scattering detector (ELSD) is then presented in Table 1 below. Table 1: Differences in related saponin components obtained according to processing methods Sample 1> Rk2 + Rh3 PPD2) DHPPD3) Rg3 Rg5 + Rki Ratio 4) Comparative Example 1 A-------B----- -C---_--Comparative Example 2 A---28 10-B---32 12 • C---25 8-Comparative Example 3 A---34 47-B---25 42-C ---22 35-Example 1 A 14 ”5 1 13 20 0.61 B 10 3 2 10 17 0.56 C 9 2 3 8 12 0.70 Example 2 A 12 8 3 11 20 0.74 B 10 5 3 10 22 0.56 C 7 3 2 6 14 0.60 Example 3 A 2 2 1 13 5 0.28 B 3 2 1 15 4 0.32 C 2 1 1 14 3 0.23 1) A: Human 蔘 B: Western 蔘 and C: Sanqi 蔘 2) PPD: Original human 蔘 2 Alcohol 3) DHPPD: 20-dehydroprotofluorene glycol 4) Ratio: (Rk2 + Rh3 + PPD + DHPPD) / (Rg3 + Rg5 + Rkl) 5) Concentration means the area of each saponin peak versus the total saponin peak Area ratio 10 As a result, non-polar saponin components such as: human invited g3, Rg5,

Rk !, Rk2, Rh3, PPD, and DHPPD in Comparative Example 1 2003200328 玖, description of the invention It was detected that it showed that the raw human 蔘 did not contain the saponin itself. However, Table 1 shows that the content of human soap Rg3 in the extract prepared by Comparative Example 2 is relatively higher than that of the other components. In the extract prepared from Comparative Example 3, the amounts of this compound g3, Rg5, and Rk! Are relative

5 is higher than other components and human donation 2, Rh3, PPD and DHPPD are not detected or just detected. However, Table 1 shows that the extracts prepared by Examples 1, 2 and 3 contained a high amount of human radon 2, Rh3, PPD and DHPPD. 10 Experimental Example 2: Anti-cancer Activity Experiment In order to confirm the anti-cancer effect of the processed extract of the genus Polygonum in the present invention, the experiment was borrowed from the literature (Carmichael, J. a / ·, Cancer /? To ·, 47 , Pp936_940, 1987). method

15 Hepatocellular carcinoma cell line (HepG2; Korea Cell Line Bank, Catalog No. 58065) was cultured with 10% FBS, 1% antibiotic-antimycin (GIBCO, Catalog No. 15240-062) and 2.2g / L bicarbonate RPMI 1640 medium and under 5% CO2 gas condition. The cell line was treated with 0.25% trypsin, detached from the culture flask and adjusted to a cell number of 3 × 104 cells / well. An equal amount of 180 μE strain was transferred to a 96-well plate, cultured in an incubator with 5% CO 2 gas at 37 ° C., and the cell line was attached to a culture flask for 24 hours. The test samples containing the extracts of the genus Polygonum from Comparative Examples 1, 2, 3 and Examples 1, 2, 3 were under high-pressure steam. 26 200304828 发明 Description of the invention Sterilized and prepared to various concentrations. 20 μL of these samples were then added to each well and incubated for 48 hours in a CO 2 incubator with 5% CO 2 gas. After 48 hours, a 50 μE MTT reaction solution (Sigma, catalog number M-5655) at a concentration of 20 mg / mL was added to each well, cultured in a C02 5 incubator for 4 hours, and the medium line was removed. lOOpL of DMSO was added to the precipitate and the optical density was measured at 580nm by an ELISA reader to determine the inhibitory effect on cell growth.

GI50 means the concentration of an inhibitory sample that inhibits 50% of the growth length of the cancer ', as shown in Table 2. 10 Results We confirmed that the anticancer efficacy of the extract of Comparative Example 3 was more effective than those of Comparative Examples 1 and 2, however, Examples 1, 2 and 3 exhibited more effective anticancer activity than that of Example 3. In summary, it was confirmed that the extract of the present invention exhibited the most effective anticancer activity, as seen in Table 2.

Table 2. Inhibitory effect of cancer cell growth (GI5G, human pupal material pg / mL) Comparative example 1 > 5000 > 5000 > 5000 Comparative example 2 1500 2040 2580 Comparative example 3 720 1200 1320 Example 1 240 300 390 Example 2 310 370 400 Example 3 480 580 600 Experimental Example 3: Anti-allergic effect To confirm the anti-allergic effect of the extract of the present invention by using RBL-2H3 cell line, 27 200304828 玖, Description of the invention This experiment was performed by the procedure described in the literature (Inagaki. Et al., / Wi, drc / z · 乂 // ergy 々? /? / · 87, pp254-259, 1988). method

The cell line (rat basophilic cell line, Korea Cell Line 5 Bank, catalog number 22256) was cultured in DMEM (Dulbecco's modified Eagle's) medium (Sigma with 10% FBS (fetal bovine serum) and L-lepinolamine) (Sigma Catalog No. D-5648, USA), using a humidified 5% C02 incubator at 37 ° C for 2 hours, and the attached cell line was floated, separated and recovered by trypsin-EDTA solution for use in cells. One step experiment. Each RBL-2H3 cell line was transferred to a 24-well plate and adjusted to 5xl05 cells / well, treated with 0.5 pg of a single mouse IgE and cultured for 12 hours to be sensitized. The cell line was washed with 0.5 mL of siraganian buffer (pH 7.2), which contained 119 mM NaCl, 5 mM KC1, 0.4 mM MgCh, 25 mM 15 PIPES, and 40 mM NaOH. Seragie buffer solution containing 5.5 mM glucose, ImM CaCl2 and 0.1% BSA was added here and cultured again at 37 ° C for 10 minutes. Thereafter, 4 (^ g) of the sample solution containing the extracts of the genus Polygonum of Comparative Examples 1, 2, 3 and Examples 1, 2, 3 was added here. After 20 minutes, the cell lines 20 were added by adding 0.02 mL of antigen, lpg / mL of DNP-BSA was activated at 37 ° C for 10 minutes, centrifuged at 2000 rpm for 10 minutes, and 0-25 mL of supernatant was transferred to a 96-well plate. 0.025 mL of ImM The p-NAG substrate is dissolved by dissolving nitrobenzene_N-acetamidine-z-D-glucosamine at 0.1M. 28 200304828 发明 Description of the invention citrate buffer solution and adjusted to pH 4.5, is added Here, it was incubated at 37 ° C for 60 minutes and 0.2 mL of a 0.1M Na2C03 / NaHC03 system was added here to end the reaction to measure its optical density at 405 nm by an ELISA reader. 5 Results

The concentration (IC5G) at which 50% of all samples are suppressed is shown in Table 3. It was confirmed that the extracts of Examples 1, 2 and 3 had more effective anti-allergic effects than Comparative Examples 1, 2 and 3 by using the allergy suppression test of ΙΒ [-2ί3 cell line (Table 3). As can be seen from Table 3, the anti-allergic efficacy of the present invention was proved to be more effective. Furthermore, by using an allergy suppression test using an RBL-2H3 cell line, the inventors confirmed that the saponin fraction and the saponin prepared in Example 7 have an antiallergic effect equal to or more effective than that of a control drug such as DSCG (color Sodium, C-0399, Sigma, USA), in particular, human soap soap RIm, Rh2, and F1 exhibited more effective inhibitory effects than DSCG (sodium tryptophan) 15 as shown in Table 4. Table 3. Anti-allergic effect on RBL cells (IC5G: human pupal material pg / mL) Comparative Example 1 > 50 > 50 > 50 Comparative Example 2 > 50 > 50 > 50 Comparative Example 3 > 50 > 50 > 50 Example 1 12 17 22 Example 2 15 19 21 Example 3 24 28 29 29 200304828 玖, Description of the invention Table 4. Antiallergic efficacy sample in RBL cells ICso saponin separation Part (1) > 0.2 Saponin separation part (2) 0.1 Fermented humans 0.18 Fermented humans 0.15 Human interest Rbi > 0.2 Humans soap Rbz > 0.2 Humans soap Re 0.06 Humans Rgi 0.08 Human soap soap Rf 0.11 20 (S) -Human soap soap Rg3 > 0.2 20 (R) -Human soap soap Rg3 > 0.2 △ 2G-Human soap soap Rg3 0.09 Human soap FI 0.13 20 (S)- Human Soap Rh2 0.03 20 (R) -Human Soap Rh2 > 0.2 Human Race Soap Rh! 0.02 20 (R) -Proto Human Sodium Glycol > 0.2 20 (S) -Proto Human Sodium Glycol > 0.2 DSCG (Forward control) 0.498

Experimental Example 4. Passive skin allergy test In order to confirm the antiallergic effect of the extracts obtained in Comparative Examples 1, 2 and 5 of Examples 4, 5, and 6, a passive skin allergy test was performed. method

A 50 μ 稀释 diluted solution containing 1 (^ g anti-dinitrophenol-human serum albumin mouse IgE serum (DNP-HSA, Sigma, USA)) was injected into ICR mice anesthetized with ether ( Dae Han Co., Ltd) was passively sensitized. After 48 hours, 0.2 mL of 0.2 mg DNP-HAS 30 200304828 was used.

A physiological saline solution and 1.6 mg of Evan blue were injected into the tail vein of the mouse, and the mouse was sacrificed by cervical dislocation to death, and then leaked to the back of the mouse. The blue dye system was measured as follows. A specific area on the back of the mouse about 1 cm2 from the IgE injection site was examined 5 times and placed in a test tube. 4mL of a mixed solution of 0.6M phosphoric acid and acetone with a mixing ratio of 5:13 was added to the test tube, and stirred and filtered. The amount of dye was measured by colorimetric analysis at 620 nm. One hour before the DNP-HAS (antibody) injection, all the extracts of Comparative Examples 1, 2 and Examples 4, 5, and 6 were dissolved or suspended in a physiological salt solution and administered orally to mice. result

It was confirmed that the antiallergic effect of the extracts of Examples 4, 5, and 6 was very effective, while the unprocessed extract of Comparative Example 1 did not exhibit antiallergic effects and the acid-treated extract of Comparative Example 2 exhibited low 15 anti-allergic effects (Table 5). Furthermore, by the anti-allergy test using RBL-2H3, the inventors confirmed that the saponin-isolated fraction and the polypeptide compound isolated from Example 7 had anti-allergic effects equal to or more effective than the control drug such as DSCG (chromic acid Nano, C-0399, Sigma, USA), specifically 'Human Soap Rh], Rh2 and F1 exhibited more effective inhibitory effects than DSCG (sodium chromate) (Table 6). 31 200304828 发明 、 Explanation of invention

Table 5. Human skin's passive skin immediate allergic efficacy Sample dose (mg / kg) Inhibition ratio (%) Comparative Example 1 50 0 Comparative Example 2 50 20 Example 4 50 52 Example 5 50 62 Example 6 50 54 DSCG (forward (Control) 100 37 Table 6. Dose inhibition ratio (%) (mg / kg) of sample for immediate skin allergic effect of passive skin Saponin fraction (1) 50 34-Saponin fraction (2) 50 47-human soap soap Rbj 50-17 human soap soap Rb2 25-12 human soap soap Re 25-15 human soap soap Rgi 25-37 human soap soap Rf 25-40 human soap soap Rg3 38 47 human soap soap Rg5 25- 45 human soap SO 25, human soap Rh2 25 36 88 human soap F4 25-63 human soap Rhj 25 79 87 human human glycol 25-25 DSCG (forward control) 100 37

As mentioned above, it has been confirmed that the processed plant of the genus Polygonum according to the present invention exhibits better treatment and protection effects against cancer or allergies than the unprocessed plants, and therefore the present invention is useful for anticancer or antiallergic drugs or health food. 32 200304828 发明 、 Explanation of invention Comparative example 5. Toxicity test Method (1)

The acute toxicity test on ICR mice (average body weight 25 ± 5g) and Sprague-Dawley rats (23 5 ± 10g, Hyochang Science) was performed using the extract of Example 1. Four groups containing 10 mice or rats were individually administered intraperitoneally with 500 mg / kg, 725 mg / kg, 1000 mg / kg, and 5000 mg / kg of test samples or solvents (0.2 mL, ip ·), and Observe for 2 weeks. Method (2) 10 The acute toxicity test on ICR mice and Sprague-Dawley rats was performed using the extract of Example 1. Four groups containing 10 mice or rats were individually orally administered intraperitoneally with 25 mg / kg, 250 mg / kg, 500 mg / kg, and 725 mg / kg of test samples or solvents (0.2 mL, ip ·), It was observed for 24 hours.

15 Results There were no treatment-related deaths, clinical symptoms, weight changes, and gross findings in either group or gender. These results suggest that the extracts prepared in the present invention are effective and safe. Hereinafter, the formulation method and the types of excipients are described, but the present invention 20 is not limited thereto. Representative preparation examples are described below. 33 200304828 Rose, description of the preparation of powder The dried powder of Example 1 50 mg lactose 100 mg talc 10 mg 5 The powder was prepared by mixing the above components and filling a sealed package. Preparation of lozenges Human tincture soap Rhl 50mg 10 Corn starch 100mg Lactose 100mg Magnesium stearate 2mg

Lozenges are prepared by mixing the above components and tabletting. 15 Preparation of capsules φ dried powder of Example 1 50 mg corn starch 100 mg milk bran 100 mg magnesium stearate 2 mg 20 capsules were prepared by mixing the above components and filling gelatin capsules by a conventional gelatin preparation method. 34 200304828 m. Description of the invention: ";; j: Preparation of injectable mandarin soap Rhl 50mg Distilled water for injection Optimum amount of pH adjuster Optimal amount 5 The preparation of injections is prepared by dissolving the active ingredients, adjusting A pH of 7.5 and thereafter is filled with all the components in a 2 mL ample and prepared by sterilization by a conventional injection preparation method.

Preparation of liquid skull 10 Dried powder of Example 1 0.1 to 80 g sucrose 5 to 10 g citric acid 0.05 to 0.3% caramel 0.005 to 0.02% vitamin C 0.1 to 1% 15 distilled water 79 to 94% co2 gas 0.5 to 0.82 %

Liquids are prepared by dissolving active ingredients, filling all of them, and sterilizing by traditional liquid preparation methods. 20 Preparation of health food Extract 1 Example 1000mg Vitamin mixture Optimum amount Vitamin A acetate 70pg 35 200304828 5 10 15 玖, Description of the invention Vitamin E 1.0 mg Vitamin B 0.13 mg Vitamin b2 0.15 mg Vitamin b6 0.5 mg Vitamin b12 0.2 | Lig Vitamin C 10mg Biotin 10pg Nicotinamide 1.7mg Folic acid calcium pantothenate 0.5mg Mineral mixture Optimum amount Ferrous sulfate 1.75mg Zinc oxide 0.82mg Magnesium carbonate 25.3mg Monopotassium phosphate 15mg Dicalcium phosphate 55mg Citric acid Potassium 90mg Calcium carbonate 100mg Magnesium chloride 24.8mg

20 The above mixture of vitamins and minerals can be changed in many ways. These changes are not considered a departure from the spirit and scope of the invention. 36 200304828

说明 Description of the invention Preparation of extract of health drink 1000mg 1000mg citrate 100Orng oligosaccharide 100g concentrated almond 2g Taurine Ig distilled water 900mL The preparation of health drink is by dissolving the active ingredients, mixing, It is prepared by stirring at 85t for 1 hour, filtering and then filling these 10-ampoules in 1000mL with all components, and sterilizing by the traditional health beverage preparation method. The invention has been described as such, it is obvious that it can be varied in many ways. Such changes are not to be regarded as a departure from the spirit and scope of the present invention, and obvious changes for those skilled in the art are intended to be included in the scope of the patent application below. Industrial application According to the present invention, a composition containing a processed human sedge plant extract exhibits an inhibitory effect on cancer or allergic diseases, and it is used for preventing or treating cancer or allergic diseases. Or the acid treatment is subsequently treated with lactic acid bacteria or enteric bacteria culture. 37

Claims (1)

200304828 Patent scope for review and review 1. A processed plant of the genus Polygonum or its extract, which contains human tincture soap (Rk2 + Rh3 + proto-human glycoside + 20-dehydroproto-human diol) The ratio (Rgs + Rgs + Rk) exceeds 0.1. 2. The processed anthracis or its 5 extracts as claimed in item 1 of the patent scope, wherein the ratio exceeds 0.2. 3. If the processed anthracis or its extract is in the scope of patent application No. 2, the ratio is more than 0.05. 4. A processed plant of the genus Polygonum or its extract, which is obtained by basically including the following steps: acid or heat, or a combination thereof. Or enteric bacteria fermentation treatment. 5. The processed anthracis plant or its extract according to item 4 of the scope of patent application, wherein the anthracis plant includes at least one selected from the group consisting of: anthracis, western salamander, Panax notoginseng, Matsue 15 cormorant, Japanese salamander, Himalayan fake salamander, Vietnamese salamander, Ayr salamander, Wang's salamander, Byping salamander and Angolan salamander. 6. The processed plant of the genus Polygonum or its extract according to item 4 of the scope of patent application, wherein the plant material comprises: roots, stems, petals, leaves, fruits, and tissue cultures thereof. 20 7. The processed human plant or its extract ’according to item 4 of the scope of the patent application, wherein the plant material includes fresh human plant, processed human village, and its by-products. 8. A method for preparing a human plant or an extract thereof as described in any one of claims 15-3 in the scope of patent application, which basically includes the following steps: 38 200304828 And other combined steps and fermentation steps followed by treatment with lactic acid bacteria or enteric bacteria. 9. A method for preparing a pharmacologically active fraction or a saponin compound, which includes the following three steps: subjecting the extract prepared by the method according to the scope of patent application to item 8 to extraction or separation of a lower alcohol to obtain A partially purified separation fraction; and additionally, the separation fraction is subjected to silica gel column chromatography to obtain an acute hormone compound from the separation fraction. 10. The method according to item 8 of the scope of patent application, wherein the method comprises the following steps: subjecting the dried plant material to an acid treatment, the acid treatment consists of: adding an acidity of about 5 to 50 times v / v% Components, culture, and alkali neutralization to obtain a chemically modified extract of the genus Polygonum; and then undergo a fermentation step consisting of adding lactic acid bacteria or enteric bacteria to the extract Cultivate to obtain processed extracts. u · The method according to item 10 of the patent application range, wherein the acid treatment is performed by 0.1 to 10% of an acidic component selected from the group consisting of: acetic acid, citric acid, lactic acid, and acidic Taste food. 12. The method of claim 8 in the scope of patent application, wherein the method comprises the steps of: subjecting the dried plant material to a heat treatment at a high temperature to obtain a chemically modified human sedge extract; and a subsequent fermentation step The fermentation step includes adding lactic acid bacteria or enteric bacteria to the extract, and culturing to obtain a processed extract. For example, the method of claim 12 of the patent scope, in which the heat treatment is applied to the patent application scope, is carried out from 110 to 180. (: Temperature range. 14. The method according to item 8 of the patent application range, wherein the fermentation step is to metabolize human adult soap Rh2, Rh3, Rk2, protozoan, Rg3, Rg5 and Rk! Bacteria and bacteria of 20-dehydroprogenylated diols. 15. The method according to item 12 of the patent application, wherein the lactic acid bacteria belong to the genus Lactobacillus or Lactobacillus. A method, wherein the lactic acid bacteria comprise at least one selected from the group consisting of the following, or a combination thereof: Bifidobacterium infantis, Bifidobacterium bifidus, Lactobacillus stagnation, Clostridium butyrate, K-103 Bifidobacterium, κ_506 Bifidobacterium, κ-513 Bifidobacterium, κ_525 Bifidobacterium, κκ-1 Bifidobacterium, and KK-2 Bifidobacterium. Method, wherein the intestinal bacteria belong to the genus Bacteroides, Clostridium or Eubacteria. 18: The method of claim 17 in the scope of patent application, wherein each of the intestinal bacteria is selected from the group consisting of At least one of them or a combination thereof: JY-6 bacilli, faeces Bacteria, κ-6. Clostridium spp. And L-8 Eubacteria. 19. A pharmaceutical composition comprising a processed content as effective in the treatment or prevention of human or mammalian cancer diseases as described in item ^ of the scope of patent application The extract is used as an active ingredient and a pharmaceutically acceptable carrier. 20. A pharmaceutical composition such as the scope of application for patent 19 items, in which the cancer 40 200304828 is applied for the scope of patent application ::.: Λ. … V &-: Vl: :: ;;, ;; / ',; · ^-·' ν '·; V: *: *, including: liver cancer, lung cancer, ovarian cancer, blood cancer, and uterine cancer. 2l · A pharmaceutical composition comprising a processed extract, such as an active ingredient, in a content effective for treating or preventing allergic diseases of humans or mammals, as an active ingredient, and 5 a pharmaceutically acceptable 22. A pharmaceutical composition comprising a saponin fraction as an active ingredient in a content effective for the treatment or prevention of allergic diseases in humans or mammals as in item 9 of the patent application scope, And a pharmacy Acceptable carrier. 10 23. A pharmaceutical composition comprising, as an active ingredient, a saponin compound effective to treat or prevent allergic diseases in humans or mammals, and a pharmaceutically acceptable carrier, the The isosaponin compounds are selected from the group consisting of: human, soap, Rh, Rb2, Re, Rgl, Rf, F1, F4, called, 仏, μ5, human, soap, Rg3, 20-human, soap, Rh , Protofluorene, and a combination thereof. 24. The pharmaceutical composition according to any one of claims 21 to 23, wherein the allergic disease includes rhinitis, dermatitis, asthma, and autoimmunity Incomplete disease. 20 25. The pharmaceutical composition according to claim 19 or 23, wherein the pharmaceutical composition is provided in an acceptable carrier and is in the form of a powder, granule, capsule, liquid medicine or injection. 26. The use of a processed extract or a saponin compound as described in any one of claims 1-3, the saponin compound is selected from 41 200304828. 5: Patent application scope:-;: > -'-. ^: ^; ≫:·-'; ί \;, ν >; 'ί ·:, -.- 5:.; ^.,: ^ ::'; V… The group formed: humans, soaps, Rbi, Rb2, Re, Rgl, Rf, FI, F4, Rh !, Rg5, 20-human moss hallucination, 20-humans, soap Rh2, original humans Alcohol and combinations thereof are used for the manufacture of a drug for cancer or allergic diseases. ^ 27. A kind of health food 'which contains the number as in the scope of patent application! The extract of any one to three items and a nutritionally acceptable additive ′ to prevent cancer or allergic diseases. 28. If the patent application covers 27 items of health food, the health food is provided as a beverage. 42 200304828 Lu, (1), the designated representative of the case is: Figure _ (2), the representative symbols of the representative diagram are briefly explained: Μ 柒, if there is a chemical formula in this case, please reveal the chemical formula that can best show the characteristics of the invention: